MDN-001 injection for liver cancer that can't be surgically removed
Part of Cancer, Digestive system clinical trials.
This trial tests an injection called MDN-001 for people with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or other local treatments. The goal is to see if it is safe and effective for patients whose cancer has not spread outside the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a diagnosis of liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or other procedures like ablation.
- You must have at least one tumor in the liver that can be measured on a CT or MRI scan, and it must be 1 cm or larger.
- Your liver function must be good enough (Child-Pugh score A or mild B, up to 7 points), and your overall health should allow you to be up and about (ECOG score 0 or 1).
- You must not have cancer that has spread outside the liver, and you must not have other types of cancer.
- Your blood counts, kidney function, and heart function must meet certain minimum levels, and any side effects from previous treatments must have mostly resolved.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
This trial tests a combination of radioactive microspheres (Yttrium-90) with targeted immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer (HCC) that cannot be surgically removed. It may be an option for those with intermediate-stage disease who haven't had prior systemic therapy.
This study tests a new medication called YMN-A02 for people with advanced liver cancer that has not responded to standard targeted and immunotherapy treatments. The goal is to see if this new drug can help shrink tumors or slow the cancer's growth.
This trial tests a treatment called yttrium-90 radioembolization (tiny radioactive beads delivered to the liver) for people with liver cancer that has already been treated before. The goal is to see if it can help control the tumor when other treatments haven't been enough.
This study tests an investigational drug called IP-001 given after surgery or microwave ablation for liver cancer. The goal is to help prevent the cancer from coming back.
This trial tests a new drug called becotatug vedotin (MRG003) for patients with advanced liver cancer that has progressed despite previous immunotherapy. The drug is designed to target cancer cells while potentially causing less harm to healthy tissue.
Hear when a new Unresectable Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.